Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Accured Expenses (2023 - 2025)

Immunocore Holdings' Change in Accured Expenses history spans 3 years, with the latest figure at -$22.0 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 1696.98% year-over-year to -$22.0 million; the TTM value through Dec 2025 reached $15.9 million, down 77.78%, while the annual FY2025 figure was $15.9 million, 77.78% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$22.0 million at Immunocore Holdings, down from $37.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $37.9 million in Q3 2025 and bottomed at -$24.5 million in Q4 2023.
  • The 3-year median for Change in Accured Expenses is $11.8 million (2023), against an average of $8.6 million.
  • The largest annual shift saw Change in Accured Expenses surged 4331.57% in 2024 before it plummeted 1696.98% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at -$24.5 million in 2023, then skyrocketed by 94.99% to -$1.2 million in 2024, then tumbled by 1696.98% to -$22.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Change in Accured Expenses are -$22.0 million (Q4 2025), $37.9 million (Q3 2025), and -$1.2 million (Q4 2024).